Narhex Life Sciences

The former Company Narhex Life Sciences Limited, through its 50% interest in Narhex Life Sciences International Limited, engaged in the research, development, and commercialization of drugs for the treatment of HIV/AIDS primarily in Australia. It focused on developing and commercializing its anti-HIV protease inhibitor DG-17. DG-17 is the water-soluble pro-drug of the active anti-HIV drug DG-35. The Company ceased trading in July 2015, following a reverse takeover by ResApp.